Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.50 |
| ▸ | PDE4A | P27815 | 5/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126336 | 0.84 | PDE4B (0.49) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3122136 | 0.81 | PDE4B (0.56) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3126364 | 0.80 | PDE4B (0.57) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3124702 | 0.77 | PDE4B (0.49) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3116876 | 0.72 | PDE4B (0.52) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2846419 | 0.72 | PDE4B (0.69) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3119047 | 0.71 | PDE4B (0.42) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3111847 | 0.70 | PDE4B (0.70) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2841461 | 0.69 | NQO2 (0.45) | PDE4BPDE4APDE4CPDE4DHPGD | |
| SCHEMBL3118083 | 0.69 | PDE4B (0.50) | PDE4BPDE3APDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| EP-2168959-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168959-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE5A, PDE2A | PDE4B 8/4885PDE3A 1/4885PDE4A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.